Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MPO | P05164 | 10/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TPO | P07202 | 9/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344368 | 0.81 | KDM4E (0.37) | ALDH1A1MPOOPRM1SMN1; SMN2TPO | |
| SCHEMBL1536784 | 0.72 | MPO (0.66) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL1460828 | 0.71 | ADORA2A (0.59) | ALDH1A1MPOSMN1; SMN2TPOADORA2A | |
| SCHEMBL1460863 | 0.68 | PDE4A (0.55) | ALDH1A1SMN1; SMN2KMT2AMEN1ADORA2A | |
| SCHEMBL1958856 | 0.67 | SMN1; SMN2 (0.46) | ALDH1A1OPRM1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL28896358 | 0.67 | MPO (0.61) | ALDH1A1MPOOPRM1SMN1; SMN2TPO | |
| SCHEMBL1959299 | 0.67 | PDE1A (0.58) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL5469805 | 0.63 | PDE1A (0.47) | ALDH1A1MPOSMN1; SMN2TPOKMT2A | |
| SCHEMBL28896211 | 0.63 | MPO (0.58) | ALDH1A1MPOOPRM1SMN1; SMN2TPO | |
| SCHEMBL9420353 | 0.63 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| EP-1824855-B1 | Novel pyrrolo [3, 2-d]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| US-20110059996-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| JP-2008522968-A | — | — | 2008-07-03 | — | — | JP | claimed |
| EP-1824855-A1 | NOVEL PYRROLO [3, 2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | claimed |
| WO-2006062465-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | claimed |
| CN-113633641-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2020-12-31 | — | — | US | disclosed |
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | ASTRAZENECA AB (SE) | 2020-09-15 | — | — | US | disclosed |
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | disclosed |
| US-20090053176-A1 | New Combination 937 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1824855-A1 | NOVEL PYRROLO [3, 2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006062465-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | MPO, CAT, SOD1 | ALDH1A1 1073/4885MPO 1/4885OPRM1 2120/4885 |
| US-20110059996-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | MPO, EPX, XDH | ALDH1A1 296/4885MPO 1/4885OPRM1 636/4885 |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | ALDH1A1 1797/4885MPO 1/4885OPRM1 2040/4885 |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | MPO, CAT, HTT | ALDH1A1 1154/4885MPO 1/4885OPRM1 2166/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | ALDH1A1 1797/4885MPO 1/4885OPRM1 2040/4885 |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | MPO, EPX, SERPINB1 | ALDH1A1 230/4885MPO 1/4885OPRM1 620/4885 |
| US-20090053176-A1 | New Combination 937 | MPO, PARK7, CAT | ALDH1A1 830/4885MPO 1/4885OPRM1 2769/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | ALDH1A1 928/4885MPO 1/4885OPRM1 2106/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | ALDH1A1 1797/4885MPO 1/4885OPRM1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.